5 Results for "

ASCVD

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "ASCVD" in MCE Product Catalog:

1
1 Cited Publications
製品番号: HY-W709553
CAS 番号: 32765-69-8
別名: Triglyceride
Glyceryl Triformate (Triglyceride) is the major form of storage and transport of fatty acids within cells and in the plasma. Glyceryl Triformate forms lipoproteins with cholesterol ester, and participates in the blood circulation. Glyceryl Triformate can lead to hypertriglyceridemia (HTG), which increases the risk of atherosclerotic cardiovascular disease (ASCVD) and pancreatitis .
loading...
    loading...
製品番号: HY-18778
CAS 番号: 866399-87-3
別名: TA-8995; DEZ-001; AMG-899
Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
loading...
    loading...
製品番号: HY-158825
CAS 番号: 2252375-14-5
別名: CIVI007 sodium
Target:  

PCSK9

研究分野:  

Metabolic Disease

Cepadacursen sodium is a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. Cepadacursen sodium can be used for hypercholesterolemia research and the prevention of atherosclerotic cardiovascular disease (ASCVD).
loading...
    loading...
製品番号: HY-18778A
CAS 番号: 866399-88-4
別名: TA-8995 sodium; DEZ-001 sodium; AMG-899 sodium
Obicetrapib (TA-8995; DEZ-001) sodium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib sodium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib sodium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
loading...
    loading...
製品番号: HY-18778B
CAS 番号: 866399-90-8
別名: TA-8995 potassium; DEZ-001 potassium; AMG-899 potassium
研究分野:  

Metabolic Disease

Obicetrapib (TA-8995; DEZ-001) potassium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potassium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib potassium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
loading...
    loading...